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ABSTRACT
Objectives: Uterine fibroids are one of the most common female disorder of the reproductive age and may cause abnormal 
uterine bleeding (UAB), pain or infertility. Our aim was to evaluate the safety and efficacy of percutaneous radio frequency 
ablation (RFA) in reducing clinical symptoms, fibroid volume and improving laboratory parameters.
Material and methods: Thirty-five symptomatic patients with 54 uterine fibroids were enrolled. Preintervention evaluation 
was made for each participant and included ultrasonography to assess the volume, largest diameter and location of the 
fibroid and Visual Analogue Scale (VAS) for quantifying the degree of menstrual pain. The magnitude of menstrual bleeding 
was scored for each patient by using pictogram. Preprocedural laboratory assessment included hemoglobulin and hema-
tocrit. Treatment efficacy was evaluated at 3, 6 and 12 months after the intervention with ultrasound (US) measurements, 
symptom scores and laboratory parameters.
Results: Pretreatment mean Hb was significantly lower than those at 3, 6 and 12 month post treatment visits (p < 0.001). 
The pretreatment median volume was significantly higher than the median volumes measured at 3, 6 and 12 months after 
RFA (p < 0.001). Visual Analogue Score (VAS) for pain was significantly lower than baseline values at 6 and 12 month visits 
(p <  0.01). Pretreatment bleeding scores and the number of patients in the predefined severe bleeding category were 
significantly decreased.
Conclusions: US guided RF ablation of uterine fibroids is relatively safe and effective procedure. It can be applied to the 
fibroids with varying localizations and sizes. It reduces the fibroid volume and obviate a need for more invasive treatment.
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INTRODUCTION 
Uterine fibroids are the most common benign tumors of 
the female reproductive system and have a significant effect 
on quality of life, economy and reproduction. Its preva-
lence was reported as 70% in Caucasian woman and 80% 
in Afro-Americans [1] .They constitute a big proportion of 
hysterectomy indications. In one report the annual cost of 
the disease and its obstetric complications was reported as 
$5.89 billion–$34.37 billion [2].
Uterine fibroids are classified in regard to their location 
in the uterus as intramural (completely or mostly localized 
within the myometrium), submucosal (projecting into the 
endometrial cavity and may be pedunculated), or sub se-
rosal (projecting outward from the serosal surface of uterus 
and may be pedunculated) [3].They may be asymptomatic 
and discovered during routine examination [4]. Neverthe-
less, almost half of the  individuals admit with clinical symp-
toms such as abnormal uterine bleeding (AUB), menstrual or 
intermenstrual pain, discomfort in pelvis region , infertility 
and consequent reduced quality of life [5, 6]. Diagnosis is 
usually made  by ultrasound (US) which enables vaginal 
exploration and is very accurate and available except large 
fundal fibroids [7] . 
Recent treatment options are medical, surgical or mini-
mally invasive techniques. Surgery is associated with com-
plications and can cause significant morbidity [8]. Moreover, 
it undesirable to women who are planning future pregnan-
cies. Myomectomy is a less invasive surgical procedure and is 
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still associated with perioperative challenges such as bleed-
ing control, adhesions, rare cases of uterine rupture and 
possible need for conversion of surgery to hysterectomy.
As the technology develops, less invasive interventional 
techniques have become more popular, which allow the 
selective destruction of the fibroids. Those are endovascular 
uterine artery embolization (UAE), high intensity focused ul-
trasound (HIFU) and radiofrequency ablation (RFA) [6, 9, 10]. 
Uterine artery embolization (UAE) isn’t target selective and 
isn’t recommended if pregnancy is desired. In addition to 
that, recurrent fibroid may develop and 20% of patients may 
require subsequent surgery [10].
RFA is an available option as a treatment modality for 
fibroids and can be performed via percutaneous or trans-
vaginal route. In this technique, energy is released directly 
within the fibroid via electrodes without giving damage to 
the adjacent tissues. RFA reduces the volume of the fibroid 
and relieves associated symptoms [11, 12]. 
Objectives
In this study, we aimed to evaluate the safety and ef-
ficacy of percutaneous RFA in relieving clinical symptoms, 
laboratory parameters and size of the fibroids in 52 weeks 
of the follow up period.
 MATERIAL AND METHODS
In this prospective study, 35 patients with symptomatic 
uterine fibroids who admitted to our tertiary center’s Gyne-
cology and Obstetrics clinics between November 2017 and 
October 2018 and required treatment were enrolled. Our 
local ethics committee approved the study protocol in ac-
cordance with principles of the Declaration of Helsinki. The 
patients recruited in the study were informed about the 
alternative treatment options including arterial emboliza-
tion and surgery and the possible advantages and risks of 
RFA before obtaining the written informed consent. None 
of them had a comorbidity which could be a contraindica-
tion for the intervention, sedation or local anesthesia. The 
patients who were younger than 18 years of age, had active 
genitourinary infection, history of coagulation abnormality, 
present pregnancy/lactation or planning pregnancy were 
excluded. 
Before the procedure all patients were assessed by the 
same gynecologist and radiologist. The gynecologist per-
formed Visual Analogue Scale (VAS) in order to quantify the 
pain. The patient was requested to choose a score between 
0–10 for dysmenorrhea (0 represented no pain and 10 was 
maximum pain). The magnitude of menstrual bleeding was 
also classified for each patient as amenorrhea, mild, mod-
erate or severe bleeding. Pictorial Blood Loss Assessment 
Chart (PBAC) was used for that purpose and score 0 was 
defined as amenorrhea, score 0–50 as mild bleeding, score 
50–100 as moderate bleeding and score > 100 as severe 
bleeding. Pretreatment evaluation included conventional 
transabdominal US and transvaginal ultrasound US (Logiq 
E9, GE Healthcare, Milwaukee, WI), equipped with a 3–5 MHz 
convex probe and a 1–6 MHz transvaginal probe. Data de-
rived from pretreatment ultrasonography assessment of 
the fibroids was composed of  the number, location (fundal, 
anterior, posterior, right side, left side, right horn, left horn), 
situation (subserosal, intramural or submucosal), the largest 
diameter  and volume (volume = 0.5233 × Anteroposterior x 
Transverse x Longitudinal Dimension). The measurements 
were repeated 3, 6 and 12 months after RFA.  Preprocedural 
hemoglobulin (Hb) and hematocrit (Htc) were recorded at 
baseline and reevaluated at 3, 6 and 12 months after RFA.
The RFA procedure was conducted in the interventional 
radiology department under intravenous (iv) sedation with 
1–3 mg of midazolam, 25–50 mcg of fentanyl or 50–120 mg 
of propofol. During the RFA, patients were in supine position 
and monitored by means of electrocardiogram (ECG), blood 
pressure and pulse. Broad-spectrum antibiotic prophylaxis 
was given an hour before the procedure. A uterine manipu-
lator was applied to allow fixation only in those patients 
whose fibroids were difficult to puncture due to either their 
rigid structure or challenging locations. Percutaneous RF 
was performed after the fibroid had been punctured under 
abdominal US monitoring by using a coaxial system with 
a 35 to 40 mm long umbrella-shaped needle-electrode 
(Med sphere, RF3000 system, Shanghai, China) (Fig. 1). One 
or more thermal ablations were performed depending on 
the size of the fibroid. Maximum intensity was 100 W during 
the ablation. The ultrasonographic appendence of the same 
fibroid before, during and after RFA were demonstrated on 
Figure 1 a–d.
After RFA, the patient was advised to take paracetamol 
for one or two days if needed and continue to the antibiotic 
treatment for one week. All complications that could be 
Figure 1a. Ultrasonıgraphic image of the uterine fibroid before RFA
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associated with RFA were recorded right after and at the 
first visit 1 week after the intervention. Patients were called 
for control visits at 3, 6 and 12 months after RFA and US 
examination, symptom scores and laboratory parameters 
were reassessed. Successful treatment was clinically con-
sidered when observing a reduction in symptoms 6 months 
after RFA. Successful treatment was also defined when the 
achieved fibroid necrosis at 6 months after treatment was 
larger than 50%.
Statistics
The Statistical Package for the Social Sciences, ver-
sion 25 (SPSS Inc., Chicago, IL, USA) was used for the 
statistical analysis. Descriptive statistics are presented 
as means ± standard deviation (SD) and medians (mini-
mum–maximum) for continuous variables and as per-
centages (%) for categorical variables The nonparametric 
Kolmogorov-Smirnov test was used to compare samples 
with the reference probability distribution, whereas the 
homogeneity of the variances assessed using the Levene 
test. The nonparametric Friedman test was used in order to 
compare initial and last measured volume and longest axis 
of the nodules before and after intervention. P < 0.05 was 
accepted as statistically significant.
RESULTS 
Thirty-five symptomatic patients with 54 uterine fi-
broids who were unresponsive to medical therapy or 
didn’t decide to undergo surgery and gave consent for RF 
treatment were enrolled in the study. The mean age was 
35.36 ± 7.362 (min–max; 25–47). Five patients were nul-
ligravida, 17 had 2 gestations whereas the remaining had 
history of  ≥ 3 previous gestations. Twenty-four patients 
had one fibroid whereas remaining eleven had multiple 
fibroids. The location of the fibroids was anterior in 16, poste-
rior in 8, fundus in 22 and 8 in the right horn. Regarding the 
type of the fibroid, 46 were intramural whereas 8 were subse-
rosal. The baseline characteristics of the patients were dem-
onstrated on Table 1. The number of ablations performed for 
each patient was 2.7 (changing between 1–5 based on size). 
There wasn’t any intervention related severe complication 
Figure 1b. RF needle placement within the fibroid during RFA
Figure 1c. Myolysis during RFA
Figure 1d. Ultrasonographic image of the fibroid after RF
Table 1. Baseline characteristics of 35 patients with 54 fibroids 
underwent RF ablation
Mean age (years) 35.36 ± 7.362
Nulligravida (number of patients) 5 
Solitary fibroid (number of patients) 24
More than 1 fibroid (number of patients) 11
Type of fibroid intramural/subserozal (number) (46/8)










RF — radio frequency
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reported after the procedure. The most prevalent complica-
tion was abdominal pain occurred in all except 2 patients 
which was mild to moderate and responsive to paracetamol 
treatment. Mild erythema and skin reaction at the entry site 
of the needle was observed in 19 patients and resolved in 
few days spontaneously without any need for topical treat-
ments. Four patients reported urinary tract infection symp-
toms despite prophylactic antibiotics and were prescribed 
oral ciprofloxacin. None of the patients experienced leuko-
cytosis, fever, nausea, fatigue or malaise after the procedure. 
Mild vaginal bleeding occurred in 12 patients that resolved 
in maximum 6 days. The mean time needed for whole pro-
cedure was approximately 45 minutes. Uterine manipulator 
was required only in five cases. All patients were discharged 
within the day of ablation and none of them required rehos-
pitalization afterwards. During the 52 weeks of follow-up, 
none of the patients needed a subsequent surgery or an-
other minimally invasive procedure. All patients attended 
the visits at 3, 6 and 12 months after RFA. The pretreatment 
mean Hb was 11.56 ± 1.65 whereas posttreatment mean Hb 
at 3,6 and 12 months were 12.5 ± 1.42, 13.17 ± 1.3 and 
13.37 ± 1.25, respectively. Posttreatment mean Hb values 
were significantly higher than pretreatment mean Hb 
(p < 0.01) whereas there wasn’t any significant difference 
between the posttreatment Hb levels at 3, 6 and 12 months 
(Tab. 2).  The pretreatment median longest diameter was 
significantly higher than posttreatment longest diameters 
(p = 0.003, p < 0.001 and p < 0.001, respectively) (Tab. 2). 
There wasn’t any statistically significant difference between 
the posttreatment median longest diameters. When intra-
mural and submucosal fibroids were compared, there wasn’t 
any statistically significant difference between the baseline 
mean longest diameters whereas posttreatment longest 
diameters were significantly smaller for intramural fibroids 
(p < 0.001) at 3, 6 and 12 months after RFA. The pretreat-
ment median volume of the fibroids was significantly higher 
than posttreatment median volumes at 3, 6 and 12 months af-
ter RFA (p = 0.007, p < 0.01 and p < 0.01, respectively) (Tab. 2). 
The median percentage of volume reduction compared 
to baseline was 36.8 % (3–72) at 3 months whereas it was 
50% (2–92) and 46.8% (1–95) at 6 and 12 months after 
RFA, respectively. When intramural and submucosal fibroids 
were compared, post treatment mean volumes at 3, 6 and 
12 months after RFA were significantly smaller and percent-
age of volume reduction was significantly higher  for intra-
mural fibroids (p < 0.001 and p = 0.024, respectively). Pre-
treatment mean VAS for menstrual pain was 7.95 ± 1.35 and 
it was significantly higher than mean VAS (p < 0.01) at post-
treatment 6 and 12 months (Tab. 2). Regarding bleeding 
severity, the number of patients who were experiencing 
severe menstrual bleeding was significantly reduced in the 
post treatment follow up (Tab. 2).
DISCUSSION
Uterine fibroids are the most common benign pelvic 
tumors. Previous studies have shown that 35% of premeno-
pausal women had a previous diagnosis of fibroid tumors 
and 51% of undiagnosed premenopausal women had ul-
trasound evidence of fibroid tumors [1]. The location of the 
tumor, volume and adjacent organs may alter the clinical 
symptoms. Current treatment modalities for uterine fibroids 
are surgery or radiological interventions which include UAE 
or RFA. A hysterectomy can completely cure the uterine 
fibroids but is considered too radical by most of the patients 
and fertility is a concern. A myomectomy is less radical, but 
it can be associated with increased intraoperative bleeding, 
postoperative infection, pelvic adhesions and omission of 
tumors, which limits its usage. UAE is a frequently used 
technique which reduces length of hospital stay and pain 
compared to the operation and patients rapidly return to 
the daily usual activities. However, UAE has the risk of rein-
tervention, and lower pregnancy and live birth rates [13].
RF ablation is used in the treatment of uterine fibroids 
and has several advantages such as low cost and obviating 
need for hospitalization. Only one applicator is necessary for 
a single patient and RF generators are widely available in the 
interventional radiology units for ablation of wide variety 
of tumors. Radiofrequency ablation can be performed via 
Table 2. Demonstration and comparison of pre and post ablation Hb, longest diameter, volume, pain and bleeding scores of the patients
Pre-ablation Post RF 3 months Post RF 6 months Post RF 12 months p*
Hb g/dL mean ± SD 11.56 ± 1.65 12.5 ± 1.42 13.17 ± 1.33 13.37 ± 4.47 p < 0.001
Longest diameter mm median (min–max) 72 (44–124) 56 (36–112) 52 (26–106) 53 (18–120) p < 0.001
Volume  mL median (min–max) 85 (17–519) 64 (13–330) 50 (3.4–372) 57(2.2–518) p < 0.001
Mean Menstrual Pain VAS 7.95 ± 1.35 6.32 ± 1.25 4.74 ± 1.32 4.47 ± 1.12 p < 0.001
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several routes such as during laparoscopy, percutaneous or 
transvaginal. In the laparoscopic approach general anesthe-
sia is required which lengthens the hospital stay [14]. How-
ever transabdominal percutaneous RF can be applied under 
sedation and allows rapid recovery and early restoration of 
the daily activities. In a previous report, percutaneous RF 
ablation with ultrasound guidance was found to be feasible 
in symptomatic patients with fibroids 4–6 cm in diameter 
[6]. In another study women with symptomatic single or 
multiple fibroids underwent percutaneous RF and followed 
for six months. RFA was successful regarding to decreasing 
fibroid volume, relieving symptoms and increasing quality 
of life [11]. Those two previously mentioned studies were 
conducted with limited number of patients (9 and 11) and 
follow up interval was short. In another study with women 
with large subserosal or intramural fibroids (> 5 cm), the 
combined treatment  with  RF following UAE  improved 
symptom severity scores significantly and  mean volume re-
duction was 56.5% [15]. In our study, the number of patients 
included was relatively higher than the previous reports and 
the size and number of the fibroids were varying in a larger 
range (4.4–12 cm). In previous reports, it was postulated that 
RFA was more effective in volume reduction in intramural fi-
broids compared to submucosal ones [6]. In accordance with 
those data, the post treatment mean longest diameter and 
volume of the fibroids were smaller in intramural fibroids 
compared to submucosal ones and volumetric response 
to RFA was better in intramural fibroids in our study. How-
ever, the number of patients with submucosal polyps was 
small and not enough to draw a definitive conclusion. RFA 
was found to be safe with mild to moderate complications 
including abdominal pain and skin erythema on the entry 
site of the needle or urinary tract infection easily managed 
with oral antibiotics and mild vaginal bleeding. RFA signifi-
cantly reduced the fibroid size and volume and none of the 
patients required subsequent treatments in one year of fol-
low up. The fibroid size and volume were significantly lower 
than basal measurements but there wasn’t any significant 
difference between post RF 3, 6 and 12 month measure-
ments. The volume reduction was most prominent on the 
6th month visit and median percentage of reduction was 
50% (min–max; 2–92). This reduction is slightly inferior to 
that shown by Bergamini et al. (77%) and Ghezzi et al. [16, 17] 
(68.8%) which may be related with the larger sizes of the 
fibroids  in our study compared to previous ones and usage 
of  US as the only imaging modality rather than more precise 
and less subjective ones such as MRI. There are studies in 
the literature using different imaging modalities such as 
contrast enhanced US or MRI [18, 19]. An MRI is particularly 
useful to define the exact  location of fibroids, being highly 
accurate  in problematic cases, such as large (> 375 mL), 
fundal or multiple (> 4) fibroids [20].  In the present study, 
menstrual bleeding score decreased significantly. According 
to self-assessment scores made before and after ablation, 
the number of patients who were experiencing severe men-
strual bleeding decreased significantly. That result was also 
reflected as increased Hb and Htc levels in the post ablation 
follow ups. VAS for menstrual pain was also reduced which 
would increase the quality of life. 
In our study, the fibroids were in various locations and 
some were difficult to reach and manipulate. Since the ra-
diologist was experienced and skilled, those challenging 
locations didn’t constitute an obstacle for RFA. In order to 
gain experience, it is advised to choose initial cases with 
one to three fundal myoma [21].
The limitation of our study was the limited number 
of patients. We need further studies with larger number 
of patients and with longer follow up to ensure that the 
volume reduction effect is durable and recurrent symptoms 
don’t reoccur by time. There is also need for further studies 
to provide information about the possible effects on endo-
metrium or future gestations.
In conclusion, US guided percutaneous RFA of uterine 
fibroids is relatively safe and effective procedure. It can be 
applied to the fibroids with varying localizations and sizes. It 
effectively reduces volume and obviate a need for more in-
vasive treatment. Besides size reduction, it also ameliorates 
the symptoms such as pain and heavy bleeding which are 
reducing the quality of life. 
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